NCT06234904View on ClinicalTrials.gov

Study of IBR733 Cell Injection in Acute Myeloid Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

August 1, 2025

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

IBR733 Cell Injection

The minimum initial dose is 5.0×10\^9 cells and then escalate to 7.5×10\^9 cells and 10.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

Imbioray (Hangzhou) Biomedicine Co., Ltd.

INDUSTRY

NCT06234904 - Study of IBR733 Cell Injection in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter